Prognostic markers in malignant lymphoma: An analysis of 1,198 patients treated at a single centre

Low, Su Enn; Horsman, Janet; Hancock, Helen; Walters, Sheetal; Hancock, B. W.

doi:10.3892/ijo.19.6.1203

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SLG model incorporated three risk factors for HD (age, albumin, lymphocyte count) and five for NHL II (age, stage, ESR, albumin and LDH). Older age (≥ 45 years), low albumin (≤35 g/l), low lymphocyte count (≤1·5 × 10 9 /1), raised ESR (> 50 mm/h), raised LDH (> 450 IU/1) and high stage (stage III and IV) were adverse factors (Low et al, 2001), and associated with increased risk or hazard of dying (and hence poorer survival).…”

Section: Resultsmentioning

confidence: 99%

“…Our previous study used markers measured on all (non‐selected) patients referred to the SLG over nearly three decades. From this, we developed an easy‐to‐use model which defined prognostic subgroupings (Low et al, 2001). In HD, the presence of the three risk factors of older age, low albumin and lymphocyte count identified a group with a 10‐year survival of less than 50% (compared with the group with no risk factor where the 10‐year survival was 90%).…”

Section: Discussionmentioning

confidence: 99%

“…As in the previous study (Low et al, 2001), we used the Kaplan–Meier method to derive survival curves for the various risk group. The survival curves of the different risk groups were then formally compared by the log‐rank test.…”

Section: Methodsmentioning

confidence: 99%

“…International collaborations have defined groupings for HD (Hasenclever & Diehl, 1998) and aggressive NHL (The International NHL Prognostic Factors Project, 1993). In a previous study (Low et al, 2001), we assessed the significance of a range of putative prognostic markers on a consecutive series of patients seen at one centre over three decades. A multivariate analysis of factors influencing prognosis showed that age, albumin and lymphocyte count were significant in predicting survival (or death) in HD and albumin, age, serum erythrocyte sedimentation rate (ESR), serum lactate dehydrogenase (LDH) and stage were significant in predicting survival (or death) in NHL II.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Risk‐adjusted prognostic models for Hodgkin's disease (HD) and grade II non‐Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients

Low¹,

Horsman²,

Walters³

et al. 2003

Br J Haematol

View full text Add to dashboard Cite

Summary. Using significant factors from multivariate analyses, based on 20 putative markers from a consecutive series of 1198 Sheffield Lymphoma Group patients, risk-adjusted prognostic models had been previously derived for Hodgkin's disease (HD) (using age, albumin and lymphocyte count) and non-Hodgkin's lymphoma (NHL) grade II (based on albumin, age, erythrocyte sedimentation rate, lactate dehydrogenase and stage). Data from 6728 patients on the British National Lymphoma Investigation database were used for validation: thus the models were applied to 4411 patients with HD and 2317 patients with NHL grade II. Survival curves derived from these validation groups confirmed our risk models. Keywords: prognostic model, lymphoma, BNLI.Although the malignant lymphomas account for less than 10% of all malignant diseases, they are important because many are potentially curable. They can be simplistically divided into Hodgkin's disease (HD), and non-Hodgkin's lymphoma grade I and II (NHL I/II). Many efforts have been made to define prognostic groupings to enable the selection of appropriate therapies. International collaborations have defined groupings for HD (Hasenclever & Diehl, 1998) and aggressive NHL (The International NHL Prognostic Factors Project, 1993). In a previous study (Low et al, 2001), we assessed the significance of a range of putative prognostic markers on a consecutive series of patients seen at one centre over three decades. A multivariate analysis of factors influencing prognosis showed that age, albumin and lymphocyte count were significant in predicting survival (or death) in HD and albumin, age, serum erythrocyte sedimentation rate (ESR), serum lactate dehydrogenase (LDH) and stage were significant in predicting survival (or death) in NHL II. Risk models were then constructed. The aim of the present study was to validate these original predictive models with a second independent patient data set provided by the British National Lymphoma Investigation (BNLI). MATERIALS AND METHODSThe original models had been constructed on data from a consecutive series of 851 patients presenting with HD (n ¼ 315) or NHL grade II (n ¼ 536) to the Sheffield Lymphoma Group (SLG) between 1970 and 1998. All patients had had histopathologically proven and untreated malignant lymphoma. To test and validate these risk models required a second independent data set. The resulting models were, therefore, applied to a series of 6728 patients (HD n ¼ 4411, NHL n ¼ 2317) from the BNLI. Table IA and B shows the distribution of patient characteristics based on the number of risk factors in the SLG and BNLI samples.As in the previous study (Low et al, 2001), we used the Kaplan-Meier method to derive survival curves for the various risk group. The survival curves of the different risk groups were then formally compared by the log-rank test. RESULTSThe SLG model incorporated three risk factors for HD (age, albumin, lymphocyte count) and five for NHL II (age, stage, ESR, albumin and LDH). Older age ( ‡ 45 years), low albumin (£ 35 ...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations